[1]

Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up[J]. Ann Oncol, 2015, 26 Suppl 5: v116−v125. DOI: 10.1093/annonc/mdv304.
[2] 高艳, 赵晋华, 宋建华, 等.  ∆SUV法和Deauville五分法在弥漫性大B细胞淋巴瘤预后中的作用[J]. 中华核医学与分子影像杂志, 2016, 36(5): 420-425.   doi: 10.3760/cma.j.issn.2095-2848.2016.05.009
Gao Y, Zhao JH, Song JH, et al.  Prognostic value of △SUV and Deauville 5-point scoring in patients with diffuse large B-cell lymphoma[J]. Chin J Nucl Med Mol Imaging, 2016, 36(5): 420-425.   doi: 10.3760/cma.j.issn.2095-2848.2016.05.009
[3] 江茂情, 陈萍, 阮新忠, 等.  化疗中期18F–FDG PET/CT显像对弥漫性大B细胞淋巴瘤的预后评估效能[J]. 中华核医学与分子影像杂志, 2018, 38(6): 395-398.   doi: 10.3760/cma.j.issn.2095-2848.2018.06.004
Jiang MQ, Chen P, Ruan XZ, et al.  Prognostic efficiency of interim 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma[J]. Chin J Nucl Med Mol Imaging, 2018, 38(6): 395-398.   doi: 10.3760/cma.j.issn.2095-2848.2018.06.004
[4] 陈虞梅, 周明舸, 刘建军, 等.  化疗中期及化疗后18F-FDG PET/CT对弥漫性大B细胞淋巴瘤患者预后判断的价值[J]. 中华核医学与分子影像杂志, 2018, 38(9): 598-601.   doi: 10.3760/cma.j.issn.2095-2848.2018.09.004
Chen YM, Zhou MG, Liu JJ, et al.  Prognostic value of interim and end-of-treatment 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma[J]. Chin J Nucl Med Mol Imaging, 2018, 38(9): 598-601.   doi: 10.3760/cma.j.issn.2095-2848.2018.09.004
[5] Burggraaff CN, de Jong A, Hoekstra OS, et al.  Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2019, 46(1): 65-79.   doi: 10.1007/s00259-018-4103-3
[6]

中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)淋巴瘤诊疗指南-2020[M]. 北京: 人民卫生出版社, 2020.

Guidelines Working Committee of Chinese Society of Clinical Oncology (CSCO). Guidelines of Chinese Society of Clinical Oncology (CSCO) Lymphoid Malignancies 2020[M]. Beijing: People's Medical Publishing House, 2020.
[7] Yim SK, Yhim HY, Han YH, et al.  Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and International Prognostic Index[J]. Ann Hematol, 2019, 98(12): 2739-2748.   doi: 10.1007/s00277-019-03834-4
[8]

Zhang YY, Song L, Zhao MX, et al. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUVmax[J/OL]. Cancer Med, 2019, 8(11): 5137−5147[2021-04-19]. https://onlinelibrary.wiley.com/doi/10.1002/cam4.2284. DOI: 10.1002/cam4.2284.
[9] Zucca E, Cascione L, Ruberto T, et al.  Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial[J]. Hematol Oncol, 2020, 38(5): 715-725.   doi: 10.1002/hon.2805
[10] Islam P, Goldstein J, Flowers CR.  PET-derived tumor metrics predict DLBCL response and progression-free survival[J]. Leuk Lymphoma, 2019, 60(8): 1965-1971.   doi: 10.1080/10428194.2018.1562181
[11] 丁重阳, 李天女, 唐立钧, 等.  18F-FDG PET/CT代谢参数判断Ⅱ~Ⅲ期弥漫大B细胞淋巴瘤的预后价值[J]. 国际放射医学核医学杂志, 2019, 43(3): 203-209.   doi: 10.3760/cma.j.issn.1673-4114.2019.03.002
Ding CY, Li TN, Tang LJ, et al.  Prognostic value of metabolic parameters for 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma of stageⅡ~Ⅲ[J]. Int J Radiat Med Nucl Med, 2019, 43(3): 203-209.   doi: 10.3760/cma.j.issn.1673-4114.2019.03.002
[12]

Laursen MB, Reinholdtz L, Schönherz AA, et al. High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients[J/OL]. Oncotarget, 2019, 10(7): 717−731[2021-04-19]. https://www.oncotarget.com/article/26588/text/. DOI: 10.18632/oncotarget.26588.
[13] Kurtz DM, Scherer F, Jin MC, et al.  Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma[J]. J Clin Oncol, 2018, 36(28): 2845-2853.   doi: 10.1200/JCO.2018.78.5246